Displaying 21–30 of 463 results
Apr 20, 2020 Beacon Stories
We checked in with a few of the Foundation’s volunteers to get their perspective on these unprecedented times.
Apr 15, 2020 Eye On the Cure Research News
A healthy diet is also important for people with retinal conditions
Apr 13, 2020 Personal Stories
Meet Sue Sanger. Sue was diagnosed with retinitis pigmentosa (RP) at the age of 29 but has continued to travel, advance in her legal and political career, and more. In the following story, Sue explains, in her own words, all she has accomplished since learning she has RP and why she’s a supporter and member of the Foundation Fighting Blindness Legacy Society.
Apr 10, 2020 The Foundation in the News
Using high-tech, camera-equipped eyeglasses and a healthy pair of eyes with 20/20 vision located hundreds, maybe even thousands, of miles away, a blind New York attorney has help to navigate the city’s busy streets and broken sidewalks.
Apr 6, 2020 Beacon Stories
Carolyn is a business professional and beauty industry leader in Raleigh, North Carolina. In spite of her diagnosis with retinitis pigmentosa, Carolyn pursues exactly what she wants and knows what she is purposed to do in her life.
The Foundation Fighting Blindness is pleased to provide a video recording and full transcript of the Accelerating Treatments for IRDs: 2020 March Progress Report. The presentation took place on March 27, 2020.
Mar 31, 2020 Eye On the Cure Research News
Company in France targets a clinical trial in 2023
Mar 31, 2020 Foundation News
The Foundation Fighting Blindness is closely monitoring the COVID-19 situation and its impact on the IRD community.
Mar 30, 2020 Science Education
An article by David Gamm, MD, PhD, a Foundation-funded researcher at the University of Wisconsin-Madison
A diagnosis of an inherited retinal disease (IRD) can be challenging for both patients and their doctors. But the Foundation can help eye care professionals provide resources and information to enable patients to better understand and manage their conditions, and potentially qualify for clinical trials of emerging therapies.